Psychedelic Vantage
@PsychedVantage
Followers
1K
Following
11K
Media
241
Statuses
2K
Venturing into the world of psychedelic drug development, research, investing, and more. Sharing insights and interviewing leading figures in the field.
Joined November 2021
Inside the PSIL ETF (NYSE: $PSIL) | Dan Ahrens @InvestinginCan1 on Psychedelic Investing.
2
4
14
Cybin Announces Senior Leadership Changes. $CYBN.
businesswire.com
Cybin Inc. (NYSE American:CYBN) (Cboe Canada:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutioni...
4
0
16
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder. $CMPS.
ir.compasspathways.com
Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from...
1
3
19
AbbVie acquired Gilgamesh’s GM-2505 (bretisilocin) in a deal worth up to $1.2B. The upfront wasn’t disclosed. What’s your estimate for the upfront payment?. (No royalties mentioned; GM-2505 has been IV in trials, with an IM formulation planned). $CMPS $MNMD $CYBN $ATAI $GHRS.
2
1
6
From: . American College of Neuropsychopharmacology Annual Meeting – December 8-11, 2024.Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD). Absolutely
0
1
17
atai Life Sciences to Participate in September Investor Conferences. $ATAI .
ir.atai.com
NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective...
0
0
6
MindMed to Participate in September Investor Conferences. $MNMD.
ir.mindmed.co
NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical…...
0
0
4
Compass Pathways to Participate in Four Investor Conferences in September. $CMPS.
ir.compasspathways.com
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate...
0
0
6
Alright, this needs to get settled: . Correct pronunciation of Mebufotenin:. $GHRS leadership: Mehboofohtenin?. $ATAI leadership: Mehboofateenin?. I am calling for a return of good ole 5-MeO-DMT! . -Jake.
3
1
23
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder. $CYBN .
ir.cybin.com
- EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia - - Recently...
0
2
13
Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA). I welcome back an old friend into the portfolio: $CYBN . As always, this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake
9
1
31
Huge validation, and yes, for programs that DON’T skip the trip 😉 . $CMPS $MNMD $CYBN $ATAI $GHRS.
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion.
2
1
20
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion.
reuters.com
AbbVie will buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion, the companies said on Monday, seeking to access a fast-growing market for psychedelic-...
1
4
34
RT @GilgameshRX: AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder,….
news.abbvie.com
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD)....
0
9
0
RT @realJoshSiegel: Awesome preprint from @kwanalexc and colleagues - . Structural rewiring in the brain after psilocybin is dependent on w….
biorxiv.org
Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the medial frontal cortex in mice. The dendritic spines would...
0
9
0
RT @atai_life: We’re proud to support @MGHNeurology and their Center for the Neuroscience of Psychedelics. The atai Research #Fellowship is….
0
6
0
RT @SunstoneHeals: Our study on the Long-Term Benefits of Single-Dose Psilocybin for Cancer-Related Depression, published earlier this summ….
0
2
0